Navigation Links
Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:10/26/2008

BOSTON, Oct. 26 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. today announced positive Phase 2 data for the Company's lead antibiotic, PTK 0796, a first-in-class aminomethylcycline (AMC). The Phase 2 study compared safety and efficacy of oral and intravenous (IV) forms of PTK 0796 to Zyvox(R) in the treatment of patients with complicated skin and skin structure infections (cSSSIs). Paratek's trial met its primary safety and tolerability endpoint, demonstrating no differences between PTK 0796 and Zyvox in incidence or pattern of adverse events (AEs). Of note, no patients discontinued therapy with PTK 0796 because of AEs, and no drug-related serious adverse events (SAEs) were seen for either drug. In the clinically evaluable population of patients (N=188), the clinical success rates were 98.0% and 93.2% for PTK 0796 and Zyvox, respectively. The Phase 2 data are being reported and discussed today at a press briefing at 10:00 a.m. and in a Late Breaker poster presentation at 12:15 p.m. at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place in Washington, D.C.

Paratek's U.S.-based Phase 2 multi-center, randomized (1:1), investigator-blinded, comparative trial enrolled 234 patients with cSSSI who required initial IV therapy. Patients were randomized to receive up to 14-days of therapy of either PTK 0796 (100mg once-daily IV with 200mg once-daily oral step-down) or Zyvox (600mg twice-daily IV with 600mg twice-daily oral step-down).

Dr. Stuart Levy, Co-founder and Chief Scientific Officer of Paratek Pharmaceuticals, stated, "New antibiotics are critically needed as multi-drug resistance grows at alarming rates in both the hospital and community settings. The Phase 2 results for Paratek's PTK 0796 are highly encouraging, particularly in context with previous findings showing activity of PTK 0796 against a broad spectrum of drug resistant bacteria, including MRSA. Overall, the Phase 2 data indicate a convincing
'/>"/>

SOURCE Paratek Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
2. Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections
3. Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014   Foundation ... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ) ... genomic profiling to biopharmaceutical companies conducting clinical trials in ... the terms of the collaboration, Foundation Medicine will license ... Foundation Medicine,s FoundationOne® assay at the WuXi Genome Center ...
(Date:10/20/2014)... 2014  Luoxis Diagnostics, Inc., a subsidiary of ... that its academic collaborators will present several peer-reviewed ... its novel RedoxSYS Diagnostic System, a first-in-class platform ... in response to injury or illness.  A poster ... clinical marker will be presented by Christopher ...
(Date:10/20/2014)... , Oct. 20, 2014  AnaptysBio, Inc., a ... antibodies, today announced the appointment of Marco ... Londei will lead the preclinical and clinical development ... "We are pleased to welcome Dr. Londei to ... , President and Chief Executive Officer of AnaptysBio. ...
Breaking Medicine Technology:Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
... Workers Ensure Emergency Deliveries are Transported , ... chapter of the American Red Cross are hard at work ... endure that could potentially put Philadelphia,s blood supply at risk. ... up a picket line yesterday when their issues were ignored ...
... , , SALT LAKE CITY, Dec. 4 ... signed a sole-source vendor agreement to provide therapy equipment and ... in Tennessee and Georgia. , "We are pleased to ... Larry K. Beardall, executive vice president of sales and marketing ...
Cached Medicine Technology:Striking Red Cross Workers Raise Public Awareness of Unsafe Working Conditions 2
(Date:10/22/2014)... October 22, 2014 For Dr. Iris Hunter, ... money; it’s an extension of her life’s mission. Her extensive ... as the owner of FirstLight HomeCare, make it clear that ... to me that my work makes a difference in the ... entrepreneurial spirit, so after much research, I felt ready to ...
(Date:10/22/2014)... California (PRWEB) October 22, 2014 Hay House ... Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) written ... of Yoga & Recovery. This book is meant to ... in a life of recovery. , Recovery 2.0 is ... 12 Steps; Recovery 2.0 is a guide for what comes ...
(Date:10/22/2014)... Weight Your Body’s Way , In a world where a ... certainly can be difficult to choose the right weight loss ... doing it the healthy way? Set aside the fads and ... exercise regularly, and choose foods with the most nutritional benefits. ... to exercise more and eat less. Despite the number of ...
(Date:10/22/2014)... Steven Reinberg HealthDay Reporter , ... add weight and length may be showing a genetic propensity ... adults, certain genes have been linked to increased body fat, ... fat and lean muscle, the researchers said. At 1 ... By ages 2 and 3, however, these genes were linked ...
(Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- Measures taken by ... in Ebola-ravaged Liberia may have limited the spread of ... report. The Firestone Natural Rubber Co. provides health ... residents of nearby densely populated communities. Between Aug. ... suspected Ebola cases among those 80,000 people. That incidence ...
Breaking Medicine News(10 mins):Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... refugees in unofficial camps are living in slum conditions redolent ... the Journal of Epidemiology and Community Health. , The research ... Gaza Displacement Centre in Beirut, Lebanon in May 2003. , ... lived in, access to outside air, the presence of mould ...
... release is also available in Spanish . ... expert on nutrition, studied the health benefits of the ... studies on the benefits of olive oil have been ... and Greece (the main olive-oil-producing countries), the incidence of ...
... increase , , THURSDAY, Jan. 17 (HealthDay News) -- The ... three decades, according to a new report released Thursday. ... Jones, senior research associate at the Guttmacher Institute, a ... will be published in the March issue of the ...
... Jan. 17 Cardiva Medical, Inc., a,privately held ... System is pleased to announce the addition of ... Cardiva as Vice President,of Finance and Chief Financial ... Business Development and Marketing., "We are very ...
... Pa., Jan. 16 With Gov. Ed,Rendell refusing to ... Exec. Dir. of the more than 65,000-member Council 13,AFSCME, ... is,mobilizing retiree members to fight back. AFSCME recently sent ... call the governor and to send,provided postcards urging him ...
... SEATTLE, Jan. 16 Hagens Berman Sobol Shapiro has ... ) and,Schering-Plough (NYSE: SGP ), manufacturers of Zetia ... Merck and Schering-Plough,violated state consumer protection laws arising from ... is the combination of Zetia and Zocor, a statin ...
Cached Medicine News:Health News:Palestinian refugees living in 'slum conditions' 2Health News:Consuming extra virgin olive oil helps to combat degenerative diseases such as cancer 2Health News:U.S. Abortion Rate Falls to Lowest Level in Decades 2Health News:U.S. Abortion Rate Falls to Lowest Level in Decades 3Health News:Cardiva Medical, Inc. Appoints Two New Officers: Malcolm Farnsworth as Vice President of Finance and Chief Financial Officer and Tara Zerby as Vice President of Business Development and Marketing 2Health News:AFSCME to Gov. Rendell: Don't Cut Health Benefits for State Retirees! 2Health News:Hagens Berman Sobol Shapiro Announces Investigation Into Marketing of Vytorin and Zetia 2Health News:Hagens Berman Sobol Shapiro Announces Investigation Into Marketing of Vytorin and Zetia 3
... neurodiagnostic for basic and advanced ... a large 12.1" XGA (1024 ... and the latest in technology ... speed, advanced NCS capabilities, advanced ...
... is a non-invasive and painless method of ... Cadwell Laboratories manufactures two magnetic stimulation devices, ... Stimulator (HSMS). The Hight Speed ... rates up to 25 Hz at full ...
... illuminated hand-held potential vision tester measures retinal ... glaucoma. Potential vision testing requires two ... or RAM (formerly known as the Illuminated ... (clip with a pinhole disc and hinged ...
... MOBEE headboxes are ... Xltek's line of portable ... with a robust new ... latest software, XLTEK's standard ...
Medicine Products: